Irina Kogan
Psychiatry · Brooklyn, NYNPI 1316352271
Payments from drug & device makers
Across 129 payments — averaging $24.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$475
- Teva Pharmaceuticals USA, Inc.$464
- Otsuka America Pharmaceutical, Inc.$399
- Lilly USA, LLC$282
- AbbVie$278
- Neurocrine Biosciences, Inc.$218
- plus $1K from 11 others
What the payments were for
- Food & beverage$3,138100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 23 | $475 |
| Teva Pharmaceuticals USA, Inc. | 16 | $464 |
| Otsuka America Pharmaceutical, Inc. | 19 | $399 |
| Lilly USA, LLC | 13 | $282 |
| AbbVie(2 entities) | 3 | $278 |
| Neurocrine Biosciences, Inc. | 10 | $218 |
| UCB, Inc. | 8 | $187 |
| Lundbeck LLC | 7 | $170 |
| Alkermes, Inc. | 7 | $169 |
| Eisai Inc. | 5 | $108 |
| Biogen | 5 | $99 |
| Pfizer | 3 | $75 |
| Indivior Inc. | 3 | $65 |
| E.r. Squibb & Sons, L.L.C. | 2 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| AstraZeneca | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,138 in reported general payments places this provider in the 85th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 22 | $64,811 |
| LybalviOlanzapine/Samidorphan Malate | 37 | $62,678 |
| Doxepin Hcl | 20 | $2,377 |
| Haloperidol Decanoate | 12 | $522 |
| Aripiprazole | 24 | $475 |
| Quetiapine Fumarate | 45 | $439 |
| Trazodone Hcl | 51 | $311 |
| Mirtazapine | 13 | $196 |
| Gabapentin | 61 | $185 |
| Olanzapine | 37 | $183 |
| Trifluoperazine Hcl | 13 | $147 |
| Zolpidem Tartrate | 34 | $118 |
| Escitalopram Oxalate | 18 | $92 |
| Benztropine Mesylate | 16 | $78 |
| Lorazepam | 21 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada, Lybalvi | $169 | $127,49059 claims |
| Lilly USA, LLCOlanzapine | $282 | $18337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Brooklyn
- Inna Yuryev-GolgerBrooklyn$3M
- Zinoviy BenzarBrooklyn$505K
- Nikhil PalekarBrooklyn$481K
- Mark OwensBrooklyn$286K
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.